Analyst firms · UBS · WST
UBS WST price target and rating history
West Pharmaceutical Services Inc. (WST) · Health Care
UBS rates West Pharmaceutical Services Inc. (WST) Buy with a $415 price target, as of its latest action on Sep 9, 2026. It has published 3 rating actions on WST since November 2022, including 1 upgrade and 0 downgrades. Across 5 firms with a WST price target in the last 12 months, the median target is $400. UBS's $415 is 4% above that.
- Current rating
- Buy
- Price target
- $415
- Median target, all firms
- $400
- Actions on WST
- 3
UBS price target on WST
Every UBS rating on WST
- Sep 9, 2026
- Dec 12, 2024
- Nov 30, 2022
How other firms rate WST
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Morgan Stanley | Overweight | $400 | Sep 22, 2026 |
| UBS | Buy | $415 | Sep 9, 2026 |
| BNP Paribas Exane | Outperform | $447 | Jul 13, 2026 |
| Barclays | Overweight | $400 | Jun 9, 2026 |
| Wolfe Research | Outperform | $375 | Jun 2, 2026 |
Questions about UBS and WST
- What is UBS's price target for WST?
- UBS's latest stated price target for West Pharmaceutical Services Inc. (WST) is $415, from its action on Sep 9, 2026.
- What is UBS's rating on WST?
- UBS rates WST Buy, a bullish rating, as of Sep 9, 2026.
- When did UBS last change its view on WST?
- On Sep 9, 2026, UBS resumes coverage at Buy, price target $415.
- How does UBS's WST target compare with other analysts?
- Across 5 firms with a WST price target in the last 12 months, the median target is $400. UBS's $415 is 4% above that.
All UBS ratingsWST news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.